Moderna pivots mRNA strategy toward oncology amid rising biotech competition

Moderna is shifting its strategic focus toward oncology by leveraging its mRNA platform for personalized cancer treatments. This transition follows positive late-stage data from the INTerpath-001 study, which evaluated the personalized cancer vaccine intismeran in combination with Merck’s Keytruda. Following these results, Moderna’s stock saw a significant increase, rising from approximately $63 in mid-August to a 52-week high of $195.71.

Parallel to these developments, the biotechnology landscape is seeing a significant shift in innovation. Chinese biotech firms are increasingly moving beyond generic manufacturing into pioneering discovery and early clinical development. Currently, nearly half of the therapeutic mRNA cancer vaccines in the global research pipeline originate from Chinese companies. This rise in innovation has led to a surge in outbound licensing deals; Chinese drugmakers completed 157 deals in 2025 with a potential value of approximately $135.7 billion, a substantial increase from the $51.9 billion in value recorded in 2024.